康恩貝(600572.SH):擬掛牌轉讓珍視明公司42%股權
格隆匯9月29日丨康恩貝(600572.SH)公佈,公司為進一步整合資源聚焦發展中藥大健康業務、打造浙江省中醫藥健康產業主平台,同時為了公司下屬江西珍視明藥業有限公司(珍視明公司)能更好地抓住眼部護理及健康產業快速發展的時機,激發珍視明公司的市場化和專業化的發展動能,公司擬通過浙江產權交易所公開掛牌轉讓所持有的珍視明公司42%股權。
根據截至評估基準日2021年6月30日的資產評估結果,珍視明公司股東全部權益評估價值為34.54億元(人民幣,下同),公司持有珍視明公司42%股權的相應評估價值為14.5068億元。
經公司十屆董事會第十二次(臨時)會議審議通過,同意以珍視明公司股東全部權益40億元作為轉讓底價依據,即公司以不低於16.80億元的掛牌底價,在浙江產權交易所掛牌轉讓珍視明公司42%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.